S&P 500 Healthcare Sector SEC Filings — March 17, 2026

17-03-2026

Citi Trends reported strong Q4 FY2025 results with total sales of $230.4M, up 9.1% YoY from $211.2M and comparable store sales growth of 8.9% (two-year stack 15.3%), alongside FY2025 sales of $820.0M, up 8.9% YoY from $753.1M with 9.7% comps growth (two-year 13.1%). Gross margins expanded 20bps to 39.9% in Q4 and 210bps to 39.6% FY, driving net income of $7.4M in Q4 (vs. $14.2M loss) and $5.2M FY (vs. $43.2M loss), with adjusted EBITDA of $11.9M Q4 (vs. $7.1M) and $11.8M FY (vs. -$14.2M, +$26M). However, SG&A expenses increased nominally to $80.0M in Q4 (vs. $77.5M) and $313.2M FY (vs. $300.2M) due to higher sales volume and incentive compensation, though leveraged 160bps and 120bps respectively on a rate basis.

• ·Opened 3 new stores, remodeled 62 locations, and closed 4 stores in FY2025.
• ·No debt and no borrowings under $75M credit facility.
• ·Q1 FY2026 quarter-to-date comparable store sales trending high-single digits.
• ·FY2026 outlook: total sales growth 6-8%, comps 5-7%, gross margin +100bps, adjusted EBITDA $34M-$38M, capex $35M-$40M, open ~25 stores, remodel 50, close 4.
• ·Equity-based compensation FY2025 totaled $5.4M; expected $5.5M-$6.0M in FY2026.

17-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) issued a press release on March 17, 2026, announcing that its RAD division received an order for 10 RIO Mini units with SARA licenses from a major Midwest construction company. No financial terms or order value were disclosed.

• ·Filing includes Exhibit 99.1: Press release dated March 17, 2026.

17-03-2026

ProCap Financial, Inc. (BRRWW) filed a DEFA14A Additional Proxy Statement on March 17, 2026. The provided content consists solely of standard forward-looking statement disclaimers, legal notices regarding securities offerings, and contact information for media and investors. No financial metrics, period-over-period comparisons, or material business updates are included.

17-03-2026

Cineverse Corp. filed a Form S-3 shelf registration statement on March 16, 2026, to register up to 21,805,701 shares of Class A Common Stock for resale by selling stockholders from time to time on Nasdaq or otherwise. The company will not receive any proceeds from these sales but has agreed to pay certain registration expenses to satisfy registration rights granted to the selling stockholders. The Common Stock (CNVS) had a last reported sale price of $2.60 per share on March 13, 2026.

• ·Registrant classified as non-accelerated filer and smaller reporting company.
• ·Incorporated in Delaware with I.R.S. Employer Identification Number 22-3720962.
• ·Principal executive offices at 224 W. 35th St., Suite 500, #947, New York, New York 10001.
• ·Par value of Common Stock: $0.001 per share.

17-03-2026

For the six months ended January 31, 2026, PURE BIOSCIENCE, INC. reported revenue growth of 21.7% YoY to $1.152M, driven by strong performance in PURE Hard Surface (+46.8% to $1.136M for the month), while SILVÉRION revenue declined sharply 91.9% to $14,000. Net loss narrowed 16.0% YoY to $1.249M amid lower G&A expenses, however interest expense rose to $195,000 from $132,000 and dilutive securities outstanding surged 63.3% to 68.6M shares. Convertible notes increased to $5.52M principal plus $625,000 accrued interest.

• ·Fiscal 2026 Notes issued totaling $720K at 6.34%-6.68% interest, maturing Oct-Dec 2028.
• ·G&A expenses decreased 10.2% YoY to $1.498M for six months.
• ·Interest expense increased 47.7% YoY to $195K for six months.

17-03-2026

McEwen Inc. reported full-year 2025 revenue of $197.6 million, up 13% YoY from $174.5 million in 2024, driven by a 48% higher average realized price of $3,532 per GEO despite a 22% decline in GEO sales from 100% owned operations to 58,552. Consolidated GEO sales fell 16% to 113,732, including an 9% drop in attributable GEOs from the San José mine to 55,180. Additionally, on February 6, 2026, McEwen Copper secured a loan facility of up to $240 million, with $28.5 million drawn to date at 12% annual interest, to fund the Los Azules Project and other purposes.

• ·Loan proceeds for McEwen Copper to be used for general corporate purposes, working capital, going public transaction costs, and advancing Los Azules Project toward Final Investment Decision.
• ·Company received 203,280 transferable warrants to purchase McEwen Copper shares at $40 per share as part of loan agreement.
• ·Argentina corporate income tax rate changed to progressive 25%-35% for fiscal years starting on/after Jan 1, 2021, with annual inflation adjustments from Jan 2022.

17-03-2026

Rallybio Corp filed an S-4 registration statement on March 17, 2026, related to a merger with Candid Therapeutics, forming a combined company with increased SEC compliance burdens post-closing, including a Super 8-K filing, 12-month ineligibility for Form S-3, and restrictions on resales for affiliates. Rallybio equityholders will receive CVRs contingent on monetizing legacy assets and cash proceeds from a July 8, 2025, Membership Interest Purchase Agreement with Recursion Pharmaceuticals, which may expire valueless if unsuccessful. The filing outlines risks such as tax uncertainty on CVRs and subordination of CVR payments.

• ·Merger agreement dated as a subsequent event on 2026-03-01.
• ·Membership Interest Purchase Agreement dated July 8, 2025.
• ·Combined company ineligible for Form S-3 for 12 full calendar months post-Closing; must wait 60 days post-Super 8-K for Form S-8.
• ·Combined company 'ineligible issuer' for three years post-Closing, restricting Form S-1 incorporation, free writing prospectuses, and WKSI status.
• ·Rule 144(i)(2) limits resale of restricted/control securities for one year after Form 10 filing.

17-03-2026

News Corporation filed an 8-K disclosing information provided to the Australian Securities Exchange (ASX) on March 16, 2026, regarding its ongoing stock repurchase program authorizing up to $1B in aggregate repurchases of Class A (NWSA) and Class B (NWS) common stock. The disclosures are attached as Exhibits 99.1 and 99.2, with no specific repurchase transaction amounts or activity detailed in the filing body itself.

• ·Securities traded on The Nasdaq Global Select Market: Class A Common Stock (NWSA, par value $0.01), Class B Common Stock (NWS, par value $0.01)

17-03-2026

On March 12, 2026, Erin Nealy Cox resigned from the Board of Directors of Sally Beauty Holdings, Inc., effective immediately, as she transitions to a new role at Walmart, Inc. There was no disagreement between Ms. Nealy Cox and the Company leading to her resignation, and her term was scheduled to expire at the 2027 Annual Meeting of Stockholders. The Company thanked her for her service and leadership.

17-03-2026

Harvard Bioscience, Inc. (HBIO) filed an 8-K on March 17, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, attaching its current corporate slide presentation dated March 2026 as Exhibit 99.1. The presentation is distributed to the investment community at conferences to provide business updates and summaries. No specific financial metrics, performance changes, or material information are disclosed in the filing itself.

17-03-2026

On March 17, 2026, the Board of Directors of Waterstone Financial, Inc. (WSBF) declared a regular quarterly dividend on its outstanding common stock ($0.01 par value, traded on NASDAQ). Details of the dividend are provided in the attached press release (Exhibit 99.1), incorporated by reference. The filing was signed by CEO William F. Bruss.

17-03-2026

For the year ended December 31, 2025, the company's revenue grew 2.5% YoY to $1,069.5M from $1,043.9M in 2024, driven by a 12.6% increase in passengers to 47.4M and 7.1% rise in air traffic movements to 481.7K; Adjusted Segment EBITDA rose 16.0% to $388.8M. However, revenue growth was modest compared to the 63% YoY surge in 2024 from $640.6M in 2023, while air traffic declined 2.0% in 2024 vs 2023 and passengers fell 3.7% that year. Risks include potential additional capex if ORSNA does not approve prior expenditures under the AA2000 Concession Agreement and delays in Florence Airport master plan approvals.

• ·Non-IFRS measures exclude cash capex requirements and interest expense on debt.
• ·Risks from inflation/hyperinflation/devaluation in AR$, EUR, BRL, UYU, AMD.
• ·Argentina uses single till model; Italy uses dual till model with regulated WACC for aeronautical activities.

17-03-2026

For the three months ended January 31, 2026, Zeo ScientifiX reported revenue growth of 33% YoY to $1.4M, with gross profit up 30% to $1.2M, and a narrowed net loss of $0.85M (improved 31% YoY) or ($0.12) per share versus ($1.2M) or ($0.20) prior year, aided by 5% lower G&A expenses. However, the company still posted an operating loss of $0.88M, and operating cash flow deteriorated to a use of $0.47M from a provision of $0.07M YoY. Cash balance rose to $1.0M at period-end, boosted by $1.3M from stock sales, while stockholders' deficit improved to $0.38M.

• ·Equity in non-marketable securities fully reserved at $145,000 as of Jan 31, 2026 (flat QoQ).
• ·Accrued payroll liabilities flat at $667,000 QoQ.
• ·Legal fees payable declined to $88,000 from $244,000 QoQ.

17-03-2026

HeartSciences Inc. filed a proxy statement for its virtual Annual Meeting of Shareholders on April 30, 2026, seeking approval for electing Andrew Simpson as Class III Director, increasing shares reserved under the 2023 Equity Incentive Plan to 1,250,000 plus Evergreen Shares, amending the Certificate of Formation for officer exculpation, ratifying Haskell & White LLP as auditors for FY ending April 30, 2026, and possible adjournment. The record date is March 6, 2026. No financial performance metrics or period-over-period comparisons are disclosed in the filing.

• ·Former company name: Heart Test Laboratories, Inc. (name change date: July 16, 2009)
• ·Meeting details: Virtual live audio webcast at https://meetings.lumiconnect.com/200-700-572-593, 10:00 a.m. Eastern Time
• ·Fiscal year end: April 30
• ·Company address: 550 Reserve Street, Suite 360, Southlake, TX 76092

17-03-2026

New Era Energy & Digital, Inc. (Nasdaq: NUAI, NUAIW) issued a Fourth Quarter FY2025 Business Update Investor Presentation on March 17, 2026, under Regulation FD Disclosure, highlighting its management team's extensive experience in energy infrastructure and digital sectors. Key executives include CEO E. Will Gray II (950+ wells developed), President Charlie Nelson (>$1B infrastructure projects), and CFO Ted Warner (>$7B data center financings), positioning the company in a structurally undersupplied AI and high-performance compute market. No financial results or period-over-period metrics were disclosed in the provided content.

• ·Former names: New Era Helium Inc. (name change date: December 9, 2024); Roth CH V Holdings, Inc. (name change date: June 25, 2024)
• ·Headquarters: 200 N. Loraine Street, Suite 1324, Midland, TX 79701
• ·Fiscal year end: December 31
• ·Emerging growth company status: Yes

17-03-2026

Daré Bioscience, Inc. completed a closing of its previously announced Regulation A offering on March 16, 2026, issuing 43,050 Investor Units at $5.00 each, for gross proceeds of $0.215M, consisting of 43,050 shares of Series A Convertible Preferred Stock and warrants to purchase 86,100 shares of common stock. This issuance represents only a small fraction of the maximum offering size of up to 4,854,000 units (potential $24.3M). The offering was qualified by the SEC on January 5, 2026.

• ·Offering statement qualified by SEC on January 5, 2026; offering circular dated January 6, 2026.
• ·Additional details on terms previously reported in 8-K filed January 29, 2026.

17-03-2026

Cibus, Inc. reported revenue of $3.6 million for the year ended December 31, 2025, down 15% from $4.3 million in 2024, while net loss improved 53% to $132.2 million from $282.7 million, primarily due to an 88% reduction in goodwill impairment to $21.0 million. Operating expenses decreased with R&D down 12% and SG&A down 13%, but a new $9.1 million long-lived assets impairment was recorded, and cash and equivalents fell to $9.9 million from $14.4 million. Net cash used in operating activities improved 13% to $50.6 million, supported by $46.6 million from financing activities.

• ·Basic and diluted net loss per share improved to $(2.78) from $(10.83), a 74% improvement.
• ·Weighted average shares outstanding increased to 45,757,376 from 23,222,256.
• ·Royalty liability to related parties increased to $234.9M from $199.4M.
• ·Equity compensation plans: 2,803,189 securities outstanding at weighted average exercise price $30.25, 2,993,104 available.

17-03-2026

Skyward Specialty Insurance Group, Inc. (SKWD) filed an 8-K/A on March 17, 2026, amending its prior 8-K to include audited financial statements of acquired Apollo Group Holdings Limited for years ended December 31, 2025 and 2024 (UK GAAP with U.S. GAAP reconciliation), and unaudited pro forma combined financial information as of and for the year ended December 31, 2025. Apollo's gross written premiums declined sharply 39% YoY to $405.9M, with net earned premiums down 42% to $253.9M, reflecting reduced scale. However, the balance on the technical account rose 11% to $76.1M, driving profit before tax up 35% to $58.8M and net profit up 33% to $49.7M.

• ·Apollo net claims incurred improved to $(144.8M) in 2025 from $(264.4M) in 2024.
• ·Net operating expenses decreased to $(51.1M) in 2025 from $(104.8M) in 2024.
• ·Acquisition consummated January 1, 2026 pursuant to share purchase agreements with 100% of Apollo shareholders; original 8-K filed January 6, 2026.

17-03-2026

New Peoples Bankshares, Inc. announced on March 17, 2026, that its Board of Directors authorized the continuation of its share repurchase program, permitting the buyback of up to 500,000 shares through March 31, 2027. No financial performance metrics or declines were reported in the filing.

• ·Filing submitted under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits)
• ·Press release attached as Exhibit 99.1

17-03-2026

Artelo Biosciences reported a widened net loss of $12.9M for FY 2025 compared to $9.8M in FY 2024, a 31% YoY increase, driven by higher operating expenses ($11.4M vs $10.1M, up 13%) and other expenses including debt extinguishment losses. Cash and equivalents dropped sharply to $0.6M from $2.3M, with stockholders' equity turning to a $1.3M deficit from a $2.9M surplus, amid ongoing going concern doubts. The company raised $6.2M net from stock issuances and $0.6M from convertible notes to fund operations.

• ·Auditor MaloneBailey, LLP highlighted substantial doubt on going concern due to recurring losses and net capital deficiency.
• ·Shelf registration on Form S-3 effective July 2023 allows sales up to $75M over three years, subject to public float limits.
• ·May 2025 convertible notes issuance: $900 gross proceeds ($350 to related parties); Oct 2025 refinancing: $692 notes ($195 related parties).
• ·June 2025 private placement: $1.4M gross proceeds from 45,618 common shares and warrants.

17-03-2026

Abra Financial Holdings, Inc. announced a definitive Business Combination Agreement dated March 16, 2026, with New Providence Acquisition Corp. III (SPAC) to go public on Nasdaq under ticker ABRX, aiming to accelerate growth in digital asset wealth management with a target of $10B+ in assets under management by end of 2027. The transaction will enable expanded product suite, including yield strategies, lending, and DeFi access via USDAF. However, it is subject to customary regulatory approvals, shareholder votes, and significant risks such as regulatory uncertainty in crypto, potential deal termination, high transaction costs, and crypto market volatility.

• ·Abra founded in 2014
• ·Business Combination Agreement dated March 16, 2026
• ·Registration Statement on Form S-4 to be filed with SEC
• ·SPAC address: 401 S County Road #2588, Palm Beach, FL 33480

17-03-2026

New Fortress Energy Inc. announced that its audited financial statements for years ended December 31, 2024 and 2023, and unaudited interim statements for 2024 and 2025 quarters, should no longer be relied upon due to errors in cash flow classification from delayed vendor payments on development projects, requiring restatement in the 2025 Annual Report on Form 10-K. The company identified additional material weaknesses in internal control over financial reporting as of December 31, 2024, with remediation plans to be detailed in the upcoming filing. On March 17, 2026, the company entered a Restructuring Support Agreement for comprehensive restructuring of its principal funded debt obligations amid ongoing creditor discussions.

• ·Errors require reclassification of certain capital expenditure payments from investing to financing activities in cash flow statements.
• ·Restatement also corrects capitalization of interest and other insignificant errors in 2025 quarters.
• ·Discussions on restructuring held confidentially with 2029 New Notes Noteholder Group, Term Loan B Group under October 30, 2023 Credit Agreement, Revolving Lender Group under April 15, 2021 Credit Agreement, and Legacy Noteholders.
• ·2025 Annual Report to be filed as soon as practicable.

17-03-2026

Ryan Specialty Holdings, Inc. issued its 2026 Proxy Statement on March 17, 2026, for the annual meeting where five director nominees (David P. Bolger, Michael G. Bungert, Francesca Cornelli, Nicholas D. Cortezi, Anthony J. Kuczinski) are standing for election to terms expiring at the 2027 annual meeting, implementing the 2025-approved board declassification toward annual elections by 2028. The board consists of 12 members (out of 13 authorized), with seven independent directors including Lead Director John W. Rogers, Jr.; Patrick G. Ryan serves as Executive Chairman since October 1, 2024, when Timothy W. Turner became CEO, separating those roles. The Ryan Parties retain board nomination rights tied to their ownership of the Original Amount from the 2021 IPO.

• ·Initial public offering (IPO) completed on July 21, 2021.
• ·Onex's board nomination right ended after share sale in April 2023.
• ·Ryan Parties' nomination rights scale with ownership of Original Amount: 100% (>50%), 50% (>40-<50%), 40% (>30-<40%), 30% (>20-<30%), 20% (>10-<20%); reduces to one nominee post Patrick G. Ryan's death/disability/involvement end if >=10%.
• ·Board held executive sessions four times a year led by Lead Director.

17-03-2026

Circle Internet Group, Inc. (NYSE: CRCL) announced the appointment of Kirk Koenigsbauer to its Board of Directors effective March 17, 2026, with service on the Compensation and Risk Committees. Mr. Koenigsbauer, currently President & Chief Operating Officer of Microsoft’s Experiences and Devices Group, brings over 30 years of experience in scaling enterprise software, cloud platforms, and security businesses, including leading the launch of Office 365 and Microsoft 365. The appointment aims to bolster Circle’s risk management, governance, and global enterprise capabilities amid its role in digital asset infrastructure.

• ·Mr. Koenigsbauer has served on the board of directors of Thomson Reuters since March 2020.

17-03-2026

Precision BioSciences, Inc. (DTIL) announced a key opinion leader (KOL) event on March 17, 2026, at 9:00 a.m. ET, featuring Aravindhan Veerapandiyan, MD, and Pat Furlong discussing the unmet needs and treatment landscape for Duchenne muscular dystrophy (DMD). The event provides an overview of the company's PBGENE-DMD program and the ongoing FUNCTION-DMD Phase 1/2 clinical trial, with presentation materials furnished as Exhibit 99.1.

• ·Live webcast and presentation materials accessible on the company’s website under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations.
• ·Information furnished under Item 7.01 is not deemed 'filed' under Section 18 of the Exchange Act.

17-03-2026

Tianci International, Inc. (CIIT) filed an 8-K announcing an amendment to its Articles of Incorporation for a 1-for-7 reverse stock split, effective March 20, 2026, at 12:01 a.m. EDT. Under the split, every seven shares of common stock ($0.0001 par value) will be combined into one fully paid, non-assessable share, with no fractional shares issued—instead, fractions are rounded up to the next whole share—and par value remaining unchanged at $0.0001 per share.

• ·Filing date: March 17, 2026
• ·8-K Items reported: 3.03, 5.03, 7.01, 9.01
• ·Old certificates will represent the adjusted number of post-split shares

17-03-2026

Pulse Biosciences, Inc. announced an organizational realignment on March 17, 2026, to accelerate development of its nsPFA electrophysiology catheters and cardiac devices for atrial fibrillation (AFib) treatment, following exceptional long-term clinical data from its first-in-human feasibility study of the nPulse Cardiac Catheter System released on February 5, 2026. The realignment involves a reduction in sales and marketing employees in the short term, while the company continues recruiting for product development functions.

• ·Principal executive offices: 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131
• ·Telephone: 510-906-4600

17-03-2026

Lifeway Foods, Inc. reported strong FY2025 results with net sales up 14% YoY to $212.5M, driven by Drinkable Kefir other than ProBugs (+18% to $181.4M), and net income surging 54% YoY to $13.9M amid gross margin expansion to 27.4% from 26.0%. However, cash and cash equivalents declined 67% to $5.6M, total current assets fell 15% to $37.1M, operating cash flow dropped 16% to $10.9M, and segments Drinkable Yogurt (-59% to $2.3M) and ProBugs Kefir (-35% to $2.2M) saw sharp declines while Cheese and Cream remained relatively flat.

• ·Investing activities cash outflow increased to $22.0M in FY2025 from $6.7M in FY2024, likely reflecting higher capex for property, plant and equipment.
• ·Accounts receivable allowance for credit losses and discounts: $1.7M (2025) vs $1.6M (2024).
• ·Debt covenants include requirements for quarterly fixed charge coverage ratio and minimum working capital ratio, with restrictions on borrowing, liens, investments, dividends, and asset sales.

17-03-2026

First Real Estate Investment Trust of New Jersey, Inc. (FREVS) filed an 8-K on March 17, 2026, under Items 2.02 and 9.01, announcing the release of its operating results for the fiscal quarter ended January 31, 2026. The press release detailing these results is attached as Exhibit 99.1. The filing was signed by Robert S. Hekemian, Jr., President and Chief Executive Officer.

• ·Principal executive offices: 505 Main Street, Suite 400, Hackensack, New Jersey 07601
• ·Telephone: (201) 488-6400
• ·Trading symbol: FREVS on OTC Pink Market
• ·Stockholder Rights Agreement dated July 31, 2023

17-03-2026

First Financial Corporation (THFF) issued its DEF 14A proxy statement for the 2026 Annual Meeting on April 15, 2026, at 11:00 a.m. EDT, held virtually at www.virtualshareholdermeeting.com/THFF2026, with a record date of February 25, 2026. Shareholders are asked to elect five director nominees (Mark J. Blade, Gregory L. Gibson, Norman D. Lowery, Paul J. Pierson, Richard J. Shagley) for terms expiring in 2029, approve a non-binding advisory vote on named executive officer compensation, and ratify Crowe LLP as independent auditors for the fiscal year ending December 31, 2026. No financial performance metrics or period-over-period comparisons are detailed in the provided filing content.

• ·Record date: February 25, 2026
• ·Meeting location: Virtual live audio webcast at www.virtualshareholdermeeting.com/THFF2026
• ·Shareholder list available for examination at headquarters (One First Financial Plaza, Terre Haute, IN 47808) beginning five days prior to meeting

17-03-2026

Coca-Cola Europacific Partners plc (CCEP) disclosed ordinary share repurchases under its buyback program on March 10, 11, 12, 13, and 16, 2026, totaling 356,157 shares across US trading venues and the London Stock Exchange, with no purchases on CBOE Europe Limited or Aquis. Daily volumes ranged from 69,090 to 77,067 shares, with VWAP prices on US venues between $100.67 and $102.33 per share and on LSE between GBP 75.13 and GBP 76.56 per share. Highest prices reached USD 103.05 and GBP 77.00, while lowest were USD 99.44 and GBP 74.20.

• ·Highest price on US venues: USD 103.0500 (March 10); Lowest: USD 99.4400 (March 11)
• ·Highest price on LSE: GBP 77.0000 (March 16); Lowest: GBP 74.2000 (March 11)

17-03-2026

WEWARDS, INC. reported zero revenues for both the three and nine months ended February 28, 2026, consistent with prior year periods. Net loss for the three months increased slightly by 0.6% YoY to $139,114, while the nine-month net loss remained essentially flat at $437,746 versus $437,848 YoY. Cash balance declined to $648,052 from $693,290 at May 31, 2025, with stockholders' deficit worsening to $(14.3M) from $(13.85M).

• ·Professional fees increased to $13,675 (3M 2026) from $12,050 (3M 2025), but nine-month total up to $57,370 from $54,875.
• ·G&A expenses declined to $718 (3M 2026) from $1,616 (3M 2025) and $2,255 (9M 2026) from $4,908 (9M 2025).
• ·Accrued interest related parties increased to $4.44M from $4.05M as of May 31, 2025.
• ·Accumulated deficit grew to $(19.56M) from $(19.12M) at May 31, 2025.